Georgia Capital — Strong Q326 NAV and healthcare expansion

29/10/2026

Georgia Capital (GCAP) delivered another strong quarter, with NAV per share increasing by 13.6% q-o-q in Georgian lari (GEL) terms to a record GEL198.91 at end-September 2026 (up 15.1% q-o-q in sterling to £57.69). This brings the first nine months of 2026 (9M26) increase to 28.6% in GEL and 35.9% in sterling. The largest contributor remained LSE-listed Lion Finance Group (LFG), whose share price increased by 26.8% q-o-q, adding 11.3pp to GCAP's NAV per share growth. Operating performance across the three large private holdings contributed another 2.4pp, while NAV-accretive buybacks added 0.6pp. An important new development is GCAP's plan to invest c GEL53m in expanding its healthcare services business over the next two to three years, focusing on private-pay specialist healthcare, outpatient services and diagnostic imaging. GCAP will contribute GEL10m, with the balance financed at the portfolio company level. Management targets a return on incremental invested capital of more than 20% once the investments are fully operational. It will also consider an IPO of the healthcare services business in the next three to five years.

Georgia Capital — Building on its balance sheet strength

22/09/2026

Georgia Capital (GCAP) enters its next phase from a considerably stronger financial position, supported by continued growth across its core holdings. Over the 12 months to end-June 2026, GCAP delivered a 49.1% sterling NAV total return (with Lion Finance Group, LFG, as the major contributor), while its share price returned 117.5%, assisted by a sharp narrowing of the discount. GCAP’s shares now trade at a 17.4% discount to its ‘live’ NAV per share (updated to LFG’s last closing price) of £56.60 as of 22 September (vs end-June 2026 NAV of £50.10). That said, we estimate that this still implies a c 39% discount to the end-June 2026 carrying value of its private portfolio, despite GCAP’s three large private businesses continuing to deliver strong growth, with aggregate revenue and EBITDA up 16.4% and 23.9% y-o-y, respectively, in H126. Strong operating cash flow and asset realisations have transformed GCAP's balance sheet: its net capital commitment (NCC) ratio declined from 31.9% at end-December 2021 to a record-low negative 2.9% at end-June 2026, and the subsequent redemption of its final $50m bond left the holding company debt-free. GCAP has therefore launched a broader GEL1bn capital-allocation programme through end-2029, covering investments in Georgia and Armenia alongside share buybacks and potentially cash dividends.

Georgia Capital — FY25 NAV total return of over 60%

26/02/2026

Georgia Capital (GCAP) delivered a very strong NAV total return (TR) of 61.2% in FY25 in Georgian lari terms (56.4% in sterling terms), aided primarily by the almost doubling share price of Lion Finance Group (LFG, which contributed 42.3pp to GCAP’s NAV TR and made up 49% of the total portfolio value at end-2025). Operating performance of GCAP’s large portfolio companies across retail (pharma), insurance and healthcare (15.4pp), as well as NAV-accretive share buybacks (11.3pp) were also significant contributors. As a result, GCAP’s five-year NAV TR to end-2025 in local currency terms reached a healthy 26.3% pa, and 19.5% pa since the de-merger of BGEO Group into Bank of Georgia (currently LFG) and GCAP in 2018. GCAP has made good progress on its current capital return programme with GEL550m of GEL700m deployed as of February 2026, supported by healthy portfolio cash flow and proceeds from the sale of the remaining 20% stake in its water utility business.